Characteristics of adult patients with ITP treated with rituximab in the “ITP-ritux registry” in France
| Patient characteristics . | . |
|---|---|
| Sex (F/M) | 159/89 (F: 64%) |
| Age (y) at ITP diagnosis, mean ± SD | 51 ± 20 |
| Duration of ITP (months), median (Q1-3) | 16 (5-72) |
| <1 y | 102 (41%) |
| ≥1 y | 146 (59%) |
| Platelet count at ITP diagnosis (×109/L), median (Q1-3) | 18 (6-41) |
| Lower platelet count in the month preceding first rituximab infusion (×109/L), median (Q1-3) | 17 (7-25) |
| Bleeding signs on ITP diagnosis | |
| None | 139 (56%) |
| Bleeding | 109 (44%) |
| No. of previous treatments for ITP, median (Q1-3) | 3 (2-4) |
| Previous treatment | |
| Steroids | 240 (97%) |
| IVIG | 175 (71%) |
| Splenectomy | 25 (10%) |
| Rituximab regimens | |
| 4 weekly infusions (4 × 375 mg/m2) | 173 (70%) |
| 2 fixed 1-g infusions (2 wk apart) | 72 (29%) |
| Other | 3 (1%) |
| Premedication with methylprednisolone | 233 (94%) |
| Dose of methylprednisolone (mg), median (Q1-3) | 63 (40-100) |
| Follow-up duration (mo), median (Q1-3) | 24 (12-30) |
| No. of patients with follow-up >12 mo | 230 (93%) |
| Patient characteristics . | . |
|---|---|
| Sex (F/M) | 159/89 (F: 64%) |
| Age (y) at ITP diagnosis, mean ± SD | 51 ± 20 |
| Duration of ITP (months), median (Q1-3) | 16 (5-72) |
| <1 y | 102 (41%) |
| ≥1 y | 146 (59%) |
| Platelet count at ITP diagnosis (×109/L), median (Q1-3) | 18 (6-41) |
| Lower platelet count in the month preceding first rituximab infusion (×109/L), median (Q1-3) | 17 (7-25) |
| Bleeding signs on ITP diagnosis | |
| None | 139 (56%) |
| Bleeding | 109 (44%) |
| No. of previous treatments for ITP, median (Q1-3) | 3 (2-4) |
| Previous treatment | |
| Steroids | 240 (97%) |
| IVIG | 175 (71%) |
| Splenectomy | 25 (10%) |
| Rituximab regimens | |
| 4 weekly infusions (4 × 375 mg/m2) | 173 (70%) |
| 2 fixed 1-g infusions (2 wk apart) | 72 (29%) |
| Other | 3 (1%) |
| Premedication with methylprednisolone | 233 (94%) |
| Dose of methylprednisolone (mg), median (Q1-3) | 63 (40-100) |
| Follow-up duration (mo), median (Q1-3) | 24 (12-30) |
| No. of patients with follow-up >12 mo | 230 (93%) |
F, female; IVIG, intravenous immunoglobulins; M, male.